These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9718631)

  • 21. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients.
    Katila H; Hurme M; Wahlbeck K; Appelberg B; Rimón R
    Neuropsychobiology; 1994; 30(1):20-3. PubMed ID: 7969854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid zinc concentrations in ex-heroin addicts and patients with schizophrenia: some preliminary observations.
    Potkin SG; Shore D; Torrey EF; Weinberger DR; Gillin JC; Henkin RI; Agarwal RP; Wyatt RJ
    Biol Psychiatry; 1982 Nov; 17(11):1315-22. PubMed ID: 6129905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype.
    Garver DL; Tamas RL; Holcomb JA
    Neuropsychopharmacology; 2003 Aug; 28(8):1515-20. PubMed ID: 12799618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Angiotensin I-converting enzyme in cerebrospinal fluid and neurosarcoidosis].
    Baudin B; Bénéteau-Burnat B; Vaubourdolle M
    Ann Biol Clin (Paris); 2005; 63(5):475-80. PubMed ID: 16230281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia.
    Samuelsson M; Skogh E; Lundberg K; Vrethem M; Öllinger K
    Psychiatry Res; 2013 Dec; 210(3):819-24. PubMed ID: 24113127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia.
    Gadelha A; Vendramini AM; Yonamine CM; Nering M; Berberian A; Suiama MA; Oliveira V; Lima-Landman MT; Breen G; Bressan RA; Abílio V; Hayashi MA
    Transl Psychiatry; 2015 Dec; 5(12):e691. PubMed ID: 26645626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers.
    Lindström LH; Ekman R; Walleus H; Widerlöv E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(1):83-90. PubMed ID: 2859636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients.
    Meltzer HY; Duncavage MB; Jackman H; Arora RC; Tricou BJ; Young M
    Am J Psychiatry; 1982 Oct; 139(10):1242-8. PubMed ID: 6127035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Renin-angiotensin system, discovered 100 years ago, has surprising effects on central nervous system].
    Wahlbeck K; Rimón R
    Duodecim; 1998; 114(21):2157-8. PubMed ID: 11757103
    [No Abstract]   [Full Text] [Related]  

  • 30. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia.
    Sasayama D; Hattori K; Teraishi T; Hori H; Ota M; Yoshida S; Arima K; Higuchi T; Amano N; Kunugi H
    Schizophr Res; 2012 Aug; 139(1-3):201-6. PubMed ID: 22742979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients.
    Kim JS; Kornhuber HH; Holzmüller B; Schmid-Burgk W; Mergner T; Krzepinski G
    Arch Psychiatr Nervenkr (1970); 1980; 228(1):7-10. PubMed ID: 6104477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low prolactin levels in cerebrospinal fluid: an after effect of lobotomy in chronic schizophrenia.
    Hyyppä MT; Liira J; Kampman R; Rimòn R
    Acta Psychiatr Belg; 1980; 80(4):452-7. PubMed ID: 7282416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia.
    Schwarz MJ; Ackenheil M; Riedel M; Müller N
    Neurosci Lett; 1998 Sep; 253(3):201-3. PubMed ID: 9792246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 36. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment.
    Zetterberg H; Jakobsson J; Redsäter M; Andreasson U; Pålsson E; Ekman CJ; Sellgren C; Johansson AG; Blennow K; Landén M
    Psychiatry Res; 2014 Jul; 217(3):143-6. PubMed ID: 24745469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme activity in cerebrospinal fluid (CSF).
    Briddon A
    Clin Chem; 1992 Mar; 38(3):439. PubMed ID: 1312400
    [No Abstract]   [Full Text] [Related]  

  • 38. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of pimozide on CSF norepinephrine in schizophrenia.
    Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE
    Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis.
    Bridel C; Courvoisier DS; Vuilleumier N; Lalive PH
    J Neuroimmunol; 2015 Aug; 285():1-3. PubMed ID: 26198911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.